FAQ
Q: Why is it not recommended to test many indicators at once?
+
A: Because the network has redundancy and time dependency. First, locate the
main axes (TNF/IL-6), then examine chemotaxis (CCL2/CXCL10), followed by braking mechanisms
(IL-10/IL-1RA), and finally assess systemic risks (IL-6/IFN-γ, etc.), which makes it easier to derive
interpretable conclusions.
Q: How can I quickly determine which type the "dominant axis" leans more towards?
+
A: Using Topic 8 Question 1: TNF-α + IL-6 Perform spindle positioning;
add branches if needed. IL-1β (Amplify/Inflammasome Clues) or IFN-β (Antiviral/Nucleic
Acid Sensing Cues).
Q: Does an increase in chemokines necessarily mean "there must be more immune cell infiltration in
the tissue"?
+
A: Not equivalent. Chemokines reflect the "recruitment signal environment,"
while actual infiltration is influenced by factors such as blood vessels, adhesion, and the tissue
microenvironment. It is recommended to treat chemokine signals as "recruitment background cues" and,
when necessary, validate them with histological or cytological evidence.
Q: Is an increase in IL-10 good or bad?
+
A: An increase in IL-10 indicates enhanced negative feedback, but it may
represent either "inflammation subsiding" or "suppression of the effect." It is recommended to compare
it with TNF/IL-6 levels from the same period and further stratify the analysis in conjunction with Topic
4.
Q: How to distinguish between "inflammation subsiding" and "immunosuppression"?
+
A: Observe whether the braking indicators (IL-10/IL-1RA/TGF-β) appear while
the pro-inflammatory background reasonably subsides. If pro-inflammatory activity remains persistently
low and braking indicators are elevated, greater consideration should be given to an inhibitory
environment (Topic 4). If pro-inflammatory activity subsides and transitions into repair signals, it
leans more toward resolution (Topic 5).
Q: Under what circumstances should attention be paid to "systemic hyperinflammation/storm-like
risk"?
+
A: When you observe multi-axis synchronous elevation (e. g., concurrent
increases in IL-6 with IFN-γ/TNF/IL-1β) accompanied by systemic symptoms or organ damage-related
endpoints, priority should be given to risk stratification and time-series tracking. (New England
Journal of Medicine)
Q: Why is IL-6 frequently included in many combinations?
+
A: IL-6 is a typical pleiotropic cytokine commonly involved in inflammatory
intensity, systemic responses, and various pathological processes. Therefore, it is suitable both as a
"principal axis intensity reading" and as a "systemic background reading."
Q: If only IL-6 is elevated, while TNF/IL-1β are not, how can this be explained?
+
A: Possible reasons include time window shifts, different types of stimuli,
or the presence of non-specific stress/tissue damage backgrounds. It is recommended to supplement with
chemotaxis (CCL2/CXCL10) and braking (IL-10/IL-1RA) for network stratification and to observe trends
using multiple time points.
